Skip to main
MSLE

MSLE Stock Forecast & Price Target

MSLE Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Satellos Bioscience is an attractive investment opportunity due to the company's promising novel drug development for Duchenne muscular dystrophy, evident in their trailblazing clinical study SAT-3247, with a potential for sustained functional benefit. With a projected future revenue of $502 million and a current cash reserve of $70 million, Satellos could generate favorable returns for investors. Key risks include clinical, regulatory, commercial, competition, and dilution, which the company plans to address through regular updates on the TRAILHEAD study's progress.

Bears say

Satellos Bioscience is currently a negative investment opportunity due to its lackluster financial performance. Its product sales, cost of sales, and collaboration revenue have all been consistently low, resulting in low total revenues and a lack of profitability. Until the company can improve its financials and show potential for growth, it is not a favorable investment for financial analysts.

MSLE has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Satellos Bioscience Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Satellos Bioscience Inc (MSLE) Forecast

Analysts have given MSLE a Strong Buy based on their latest research and market trends.

According to 3 analysts, MSLE has a Strong Buy consensus rating as of Aug 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $20.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $20.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Satellos Bioscience Inc (MSLE)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.